Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Contributing sentiments towards policy:

49% : This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc ("Arecor" or the "Company") Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million * AT278 (500U/mL) is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems * Arecor and Sequel Med Tech, LLC to commit up to $1.3 million each to fund development work in preparation for pivotal Phase 2 trial for AT278-Insulin Pump programme *
46% : Cash runway extended to 1H 2027 Cambridge, UK, 25 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, has signed a co-development agreement with Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, to combine AT278 (500U/mL) with Sequel's twiist Automated Insulin Delivery (AID) system powered by Tidepool, and a royalty financing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand") which will raise non-dilutive capital of up to $11 million (£8.2 million).

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.